Oncology Drug Articles & Analysis
60 news found
Following the generation of successful results with the University of Michigan through the ACE program, Predictive Oncology is now actively calling for submissions for a new cohort of compounds to be tested in Q4 2025. ...
Their unique technology as well as high quality bioink, provide revolutionary capabilities to the wider life science and drug discovery market. Their extensive knowledge in 3D bioprinting combined with our expertise in oncology and 3D modelling will help fulfil our shared commitment to accelerate oncology drug development ...
ByCELLINK
Mulinacci added, “I look forward to working with the team at Araris to expand on its business development efforts as they further advance their oncology pipeline of next-generation antibody-drug conjugates (ADCs) into the clinic. ...
The Company believes its technologies will become widely adopted for use in the fields of regenerative medicine, oncology, neurology, and drug development, enabling the Company to build a new, global life science business franchise. ...
“Antengene believes that cancer treatments involving the rational combination of immuno-oncology drugs and targeted therapies may offer the greatest opportunity for substantial advances in treatment outcomes for patients with cancer,” said Dr. ...
The company’s mission is to lead a revolution in oncology therapy by delivering its innovative and targeted intra-arterial (IA) delivery of chemotherapy directly to solid tumors. ...
ByxCures
(Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a virtual fireside chat at the Bank of America 2022 Biotech SMID Cap Conference ...
(Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the first 13 patients have been dosed in Part 1 of the pivotal Phase 3 SERENITY III trial investigating at-home use of BXCL501 (dexmedetomidine) sublingual film, the Company’s proprietary, ...
Ardigen, a global leader in artificial intelligence for drug discovery, is proud to announce that Agnieszka Blum, MD, PhD has joined the company’s Board of Management. She brings with her extensive knowledge and experience in the field of Immuno-Oncology and drug discovery, which is strategic for Ardigen’s development. ...
ByArdigen
(KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company’s first immuno-oncology drug candidates, at SITC (Society for Immunotherapy of Cancer) Annual Meeting taking place November 8-12 in Boston. ...
SEATTLE, Sept. 27, 2022 (GLOBE NEWSWIRE) -- SEngine Precision Medicine Inc., a Seattle-based precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures, is conducting a Non-Small Cell Lung Cancer (NSCLC) study at the esteemed Johns Hopkins University. ...
(Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth ...
(Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the National Institute on Drug Abuse, part of the National Institutes of Health (NIH), has awarded Columbia University a multi-year NIDA grant to fund clinical ...
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine has now raised a total of $19M, following the recent closing of a $10M Series A2, as it continues to commercialize a platform that matches cancer patients to the right drug and also drives drug discovery. ...
Ariana Pharma, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial Officer. ...
BillionToOne, Inc., a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of its first oncology liquid biopsy products, Northstar Select™ and Northstar Response™. ...
In addition, the center comprises a newly established research team focused on leveraging chemical biology techniques to further propel the company’s oncology drug development process. “Our new Bayer research and innovation center at Kendall Square is part of our strategy to be at the forefront of scientific discovery and breakthrough innovation for ...
ByBayer AG
"I’m impressed by the pipeline’s breadth of novel, first-in-class programs in oncology and immunology. These programs are nearly all targeting proteins the industry has previously viewed as undruggable and indicate the potential to deliver enormous value to patients if successful. ...
ByBayer AG
The experts discussed the role of EsoCap’s technology for the topical treatment of Barrett esophagus and explored the application of EsoCap’s drug delivery platform in combination with monoclonal antibodies, siRNA-based technology, oncology drug substances as well as other agents. ...
Our synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with these Gene Circuit technologies, to target particularly challenging liquid and solid tumor oncology indications. Our lead programs include SENTI-202 and SENTI-301. ...